Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Camurus ABCAMRF 81 Net Cash per Share is $6.08 as of Jun. 2026, which is 76% below its 10-year median of 25.10. GuruFocus rates CAMRF with a GF Score™ of 81/100 and a GF Value™ of $73.98 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 804 Biotechnology companies, Camurus AB ranks worse than 71.64% on this metric.
Camurus AB (OTCPK:CAMRF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Camurus AB Net Cash per Share Related Terms
Camurus AB Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Camurus AB's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, RVMD: Net Cash per Share Comparison
For the Biotechnology subindustry, Camurus AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Camurus AB's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Camurus AB's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a Net Cash per Share of $6.08 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Camurus AB and its competitors. This is 76% below median its historical median of 25.10. Over the past decade, Camurus AB's Net Cash per Share has ranged from 8.32 to 169.89. According to the industry distribution chart, Camurus AB ranks #576 out of 804 companies in the Biotechnology industry, placing it in the top 71.6%.
Is Camurus AB's Net Cash per Share too high?
Camurus AB's current Net Cash per Share of $6.08 is 76% below median its 10-year median of 25.10. Over the past 10 years, this metric has ranged from a low of 8.32 to a high of 169.89. The Biotechnology industry median Net Cash per Share is 5.02. Camurus AB's value of $6.08 is 21.2% above this industry median. Based on the distribution chart, Camurus AB ranks #576 out of 804 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Camurus AB has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #576 out of 804 companies for Net Cash per Share. This places Camurus AB in the lower half of its industry. The industry median Net Cash per Share is 5.02. Camurus AB's value of $6.08 is 21.2% above this benchmark. Historically, Camurus AB's own Net Cash per Share has ranged from 8.32 to 169.89 over the past decade. While the company's 10-year median is 25.10 vs. the industry median of 5.02, Camurus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.02, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Net Cash per Share of $6.08 is 21.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Net Cash per Share is $6.08, which is 76% below median its own 10-year median of 25.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $73.98, compared to a current price of $58.51 — trading 20.9% below its estimated fair value. The current Net Cash per Share is $6.08, which is 76% below median its 10-year median of 25.10 and 21.2% above the Biotechnology industry median of 5.02. Camurus AB's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Net Cash per Share is $6.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $58.51 is trading 20.9% below its estimated GF Value™ of $73.98.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
Net Cash per Share: $6.08 (76% below median its 10-year median of 25.10)
GF Value™: $73.98 vs. price of $58.51 (20.9% below fair value)
Industry Position: 21.2% above the Biotechnology median (#576 of 804)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
81GF Score
Get the complete analysis for CAMRF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
